The long term goal of this work is to determine the mechanism of action of steroid antagonists and the molecular basis for cellular resistance to anti-steroids that frequently develops in breast cancer. This proposal will focus on progesterone receptor (PR) and progesterone antagonists and thus will build on an experimental system that we have developed over several years. Based on our biochemical studies of PR and the biological behavior of current anti-progestins, in particular functional switching from antagonists to agonists by cAMP signaling pathways, we propose the following hypotheses: I) Anti-progestins bound to PR act in part as trans- repressors of receptor in the same cell bound to agonist. 2) Cellular resistance to anti-steroids can be explained by enhancement of the activation potential of the receptor-antagonist complex by alternate signal transduction pathways. This proposal will use combined biochemical, molecular and genetic approaches to investigate these novel mechanisms.
AIM #1 will determine whether anti-progestins can act in vivo as transrepressors by combined mechanisms of heterodimerization and competition for binding to specific DNA. On approach will rely on use of ligand specificity PR mutants (agonist or antagonist specific) for detection and functional analysis of heterodimers in the intact cell. Promoter interference will be used to determine the extent to which ligand specific PRs can compete for binding to DNA in vivo.
AIM #2 will determine whether different classes of anti-progestins promote the same or different conformational changes in PR structure and will correlate these changes with biological properties as either weak or strong transrepressors.
AIM #3 will isolate the cellular gene products involved in mediating the uncovering of the transcriptional potential of the PR-antagonist by alternate signaling pathways. We will use a powerful genomic mutagenesis and selection strategy with a functional PR system reconstituted in yeast.
Aim 3, therefore, will provide important first steps toward proving our hypothesis for cellular resistance to anti-steroids and for dissecting the molecular mechanisms that mediate signal transduction pathway crosstalk. The expectation of this research is to enhance our knowledge of steroid hormone action in general and to uncover novel receptor mechanisms that may explain the biological behavior of anti-progestins. Further, the hope is that mechanistic information derived from these studies can be exploited to improve the efficacy of current steroid antagonists as therapeutic agents or to develop novel antagonists.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Project (R01)
Project #
5R01DK049030-02
Application #
2149591
Study Section
Diabetes, Endocrinology and Metabolic Diseases B Subcommittee (DDK)
Project Start
1994-09-30
Project End
1998-08-31
Budget Start
1995-09-01
Budget End
1996-08-31
Support Year
2
Fiscal Year
1995
Total Cost
Indirect Cost
Name
University of Colorado Denver
Department
Pathology
Type
Schools of Medicine
DUNS #
065391526
City
Aurora
State
CO
Country
United States
Zip Code
80045
Elsarraj, Hanan S; Valdez, Kelli E; Hong, Yan et al. (2017) NEMO, a Transcriptional Target of Estrogen and Progesterone, Is Linked to Tumor Suppressor PML in Breast Cancer. Cancer Res 77:3802-3813
Grimm, Sandra L; Hartig, Sean M; Edwards, Dean P (2016) Progesterone Receptor Signaling Mechanisms. J Mol Biol 428:3831-49
TreviƱo, Lindsey S; Bolt, Michael J; Grimm, Sandra L et al. (2016) Differential Regulation of Progesterone Receptor-Mediated Transcription by CDK2 and DNA-PK. Mol Endocrinol 30:158-72
Moore, Nicole L; Edwards, Dean P; Weigel, Nancy L (2014) Cyclin A2 and its associated kinase activity are required for optimal induction of progesterone receptor target genes in breast cancer cells. J Steroid Biochem Mol Biol 144 Pt B:471-82
Simons Jr, S Stoney; Edwards, Dean P; Kumar, Raj (2014) Minireview: dynamic structures of nuclear hormone receptors: new promises and challenges. Mol Endocrinol 28:173-82
Obr, Alison E; Grimm, Sandra L; Bishop, Kathleen A et al. (2013) Progesterone receptor and Stat5 signaling cross talk through RANKL in mammary epithelial cells. Mol Endocrinol 27:1808-24
Obr, Alison E; Edwards, Dean P (2012) The biology of progesterone receptor in the normal mammary gland and in breast cancer. Mol Cell Endocrinol 357:4-17
Garza, Anna S; Khan, Shagufta H; Moure, Carmen M et al. (2011) Binding-folding induced regulation of AF1 transactivation domain of the glucocorticoid receptor by a cofactor that binds to its DNA binding domain. PLoS One 6:e25875
Wardell, Suzanne E; Narayanan, Ramesh; Weigel, Nancy L et al. (2010) Partial agonist activity of the progesterone receptor antagonist RU486 mediated by an amino-terminal domain coactivator and phosphorylation of serine400. Mol Endocrinol 24:335-45
Holley, Aaron K; Kiningham, Kelley K; Spitz, Douglas R et al. (2009) Progestin stimulation of manganese superoxide dismutase and invasive properties in T47D human breast cancer cells. J Steroid Biochem Mol Biol 117:23-30

Showing the most recent 10 out of 28 publications